Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases.

ABSTRACT:

Background

Rituximab is commonly used to treat patients with primary glomerular diseases; however, its pharmacokinetics in this population have not been fully described yet.

Materials and methods

This single-center, open-label, uncontrolled clinical trial included adult patients with glomerular diseases who required rituximab treatment (NEFRTX; EudraCT: 2020-000484-23). Patients received 1 or 0.5 g of rituximab on day 1 (and d14 in some cases). Blood and urine samples were collected at days 1, 7, 14, 28, and 45 to measure biochemical parameters (proteinuria, albuminemia, plasma immunoglobulin, and urine immunoglobulin), rituximab, and antidrug antibody concentrations. The gene encoding the neonatal fragment-crystallizable receptor was also characterized. Linear regression an

SUBMITTER: Larrosa-Garcia M 

PROVIDER: S-EPMC12588639 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature